{"id":32645,"date":"2025-04-29T12:05:19","date_gmt":"2025-04-29T04:05:19","guid":{"rendered":"https:\/\/flcube.com\/?p=32645"},"modified":"2025-04-29T12:05:20","modified_gmt":"2025-04-29T04:05:20","slug":"cspc-pharmaceutical-reports-7-8-revenue-decline-in-2024-amid-vbp-impact","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32645","title":{"rendered":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact"},"content":{"rendered":"\n<p>China-based CSPC Pharmaceutical Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.<\/p>\n\n\n\n<p><strong>Impact of VBP on Core Products<\/strong><br>CSPC&#8217;s oncology business revenues fell by 28% in 2024, largely due to significant price cuts for key products. Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) and liposomal doxorubicin saw their prices reduced by 58% and 23%, respectively, during the Beijing-Tianjin-Hebei &#8220;3+N&#8221; alliance VBP tender. Additionally, Conjupri (levamlodipine) was affected, though it did not secure a spot in the VBP round.<\/p>\n\n\n\n<p><strong>Regulatory and Development Milestones<\/strong><br>Despite the revenue decline, CSPC achieved notable regulatory milestones in 2024, including 16 marketing approvals, 66 clinical approvals, and 3 breakthrough therapy designations in China. The company also expanded its global footprint by establishing a US formulation sales company and a Southeast Asian new drug development division. CSPC remains committed to accelerating the development and expansion of high-end complex injection formulations, monoclonal and bispecific antibodies, and other biological preparations, as well as inhalers in the European and American markets.<\/p>\n\n\n\n<p><strong>Global Expansion Initiatives<\/strong><br>CSPC continued its global expansion by setting up subsidiaries in countries along the Belt and Road Initiative, including Singapore, Thailand, Malaysia, and Vietnam. The company also engaged in new drug development partnerships with strategic clients in Indonesia and the Philippines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042803183_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025042803183_c.\"><\/object><a id=\"wp-block-file--media-96a32f77-4665-4d40-acae-ad510566f232\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042803183_c.pdf\">2025042803183_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025042803183_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-96a32f77-4665-4d40-acae-ad510566f232\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32648,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[171,27,855,82],"class_list":["post-32645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cspc-pharmaceutical","tag-finanical-reports","tag-hkg-1093","tag-vbp-voluem-based-procurement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32645\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact\" \/>\n<meta property=\"og:description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32645\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T04:05:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-29T04:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact\",\"datePublished\":\"2025-04-29T04:05:19+00:00\",\"dateModified\":\"2025-04-29T04:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645\"},\"wordCount\":252,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2902.webp\",\"keywords\":[\"CSPC Pharmaceutical\",\"Finanical Reports\",\"HKG: 1093\",\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32645#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32645\",\"name\":\"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2902.webp\",\"datePublished\":\"2025-04-29T04:05:19+00:00\",\"dateModified\":\"2025-04-29T04:05:20+00:00\",\"description\":\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32645\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2902.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32645#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact - Insight, China&#039;s Pharmaceutical Industry","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32645","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact","og_description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.","og_url":"https:\/\/flcube.com\/?p=32645","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-29T04:05:19+00:00","article_modified_time":"2025-04-29T04:05:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32645#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32645"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact","datePublished":"2025-04-29T04:05:19+00:00","dateModified":"2025-04-29T04:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32645"},"wordCount":252,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","keywords":["CSPC Pharmaceutical","Finanical Reports","HKG: 1093","VBP (voluem-based procurement)"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32645#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32645","url":"https:\/\/flcube.com\/?p=32645","name":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32645#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","datePublished":"2025-04-29T04:05:19+00:00","dateModified":"2025-04-29T04:05:20+00:00","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) reported its 2024 financial results, showing a 7.8% year-on-year (YOY) decline in total revenues to RMB 29 billion (USD 4 billion). This marks the first time in nearly five years that CSPC has experienced a performance decline, primarily due to the involvement of core products in volume-based procurement (VBP) tenders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32645#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32645"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32645#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","width":1080,"height":608,"caption":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32645#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32645"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32645\/revisions"}],"predecessor-version":[{"id":32649,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32645\/revisions\/32649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32648"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}